Multiple myeloma: signaling pathways and targeted therapy
Q Lu, D Yang, H Li, T Niu, A Tong - Molecular Biomedicine, 2024 - Springer
Multiple myeloma (MM) is the second most common hematological malignancy of plasma
cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the …
cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the …
Targeting Minimal Residual Disease
YT Chou, P Allegakoen… - Annual Review of Cancer …, 2024 - annualreviews.org
Minimal residual disease (MRD) represents a significant challenge in the treatment of
various cancers, acting as a precursor to relapse and therapeutic resistance. This review …
various cancers, acting as a precursor to relapse and therapeutic resistance. This review …
Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease
M Johansen, MB Levring, K Stokbro, M Diaz-delCastillo… - Cancers, 2023 - mdpi.com
Simple Summary Multiple myeloma is the second most common hematological malignancy,
and the majority of patients have osteolytic lesions by the time of diagnosis. Bone …
and the majority of patients have osteolytic lesions by the time of diagnosis. Bone …
Targeting CAM-DR and mitochondrial transfer for the treatment of multiple myeloma
R Suzuki, D Ogiya, Y Ogawa, H Kawada, K Ando - Current Oncology, 2022 - mdpi.com
The prognosis of patients with multiple myeloma (MM) has improved dramatically with the
introduction of new therapeutic drugs, but the disease eventually becomes drug-resistant …
introduction of new therapeutic drugs, but the disease eventually becomes drug-resistant …
TTK promotes multiple myeloma progression by regulating RGN expression
XF Zhu, Z Feng, X Peng, T Di, YH Li, J Bai, T Ma, L Li… - 2024 - researchsquare.com
Multiple myeloma (MM) is a malignant proliferative disorder of plasma cells and remains an
incurable disease. Threonine and tyrosine kinase (TTK) is a dual-specific protein kinase that …
incurable disease. Threonine and tyrosine kinase (TTK) is a dual-specific protein kinase that …
Inhibition of PI3K class IA kinases using GDC-0941 overcomes cytoprotection of multiple myeloma cells in the osteoclastic bone marrow microenvironment enhancing …
H Kikuchi, E Amofa, M Mcenery, SA Schey… - Cancers, 2023 - mdpi.com
Simple Summary The activation of osteoclasts occurs in up to 80% of myeloma patients.
Osteoclasts promote myeloma resistance to therapeutic treatments and the formation of …
Osteoclasts promote myeloma resistance to therapeutic treatments and the formation of …